Lead Product(s) : Relugolix
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Relugolix is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Menorrhagia.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
November 04, 2024
Lead Product(s) : Relugolix
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Aminolevulinic Acid Hexylester
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Asieris Announces NDA Acceptance for Regulatory Review of Cevira in China
Details : APL-1702 (cevira) is a photodynamic drug-device combination product in development for the non-surgical treatment of high-grade squamous intraepithelial lesions, licensed to Asieris by Photocure.
Product Name : Cevira
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 12, 2024
Lead Product(s) : Aminolevulinic Acid Hexylester
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : GenSci094
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Phase III
Sponsor : Sixth Affiliated Hospital, Sun Yat-sen University
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : GenSci094 is a drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Infertility.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
October 19, 2023
Lead Product(s) : GenSci094
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Phase III
Sponsor : Sixth Affiliated Hospital, Sun Yat-sen University
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : SHR7280
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : SHR7280 is a drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Infertility, Female.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
August 16, 2023
Lead Product(s) : SHR7280
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Elagolix Sodium
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Elagolix is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Endometriosis.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
December 13, 2022
Lead Product(s) : Elagolix Sodium
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : QL1012
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Efficacy and Safety of QL1012 in Women for Assisted Reproductive Treatment
Details : QL1012 is a drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Infertility.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
December 08, 2021
Lead Product(s) : QL1012
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Aminolevulinic Acid Hexylester
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Asieris has received Clinical Trial Approval from China NMPA for the global, multi-centered Phase III clinical trial of its photodynamic drug-device combination product Cevira®, which is being developed for the non-surgical treatment of high-grade cerv...
Product Name : Cevira
Product Type : Miscellaneous
Upfront Cash : Inapplicable
July 08, 2020
Lead Product(s) : Aminolevulinic Acid Hexylester
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Triptorelin Pamoate
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Phase III
Sponsor : Peking University Third Hospital | The First Affiliated Hospital with Nanjing Medical University | Women’s Hospital, Zhejiang University School of Medicine | Xiangya Hospital, Central South University | Sixth Affiliated Hospital, Sun Yat-sen University |
Deal Size : Inapplicable
Deal Type : Inapplicable
Clinical Study of Recombinant Human Follitropin for Injection Assisted in COH Assisted IVF-ET
Details : Triptorelin is a Protein drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Ovarian Hyperstimulation Syndrome.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
March 06, 2017
Lead Product(s) : Triptorelin Pamoate
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Phase III
Sponsor : Peking University Third Hospital | The First Affiliated Hospital with Nanjing Medical University | Women’s Hospital, Zhejiang University School of Medicine | Xiangya Hospital, Central South University | Sixth Affiliated Hospital, Sun Yat-sen University |
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Follitropin Alfa
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Phase III
Sponsor : Peking University People's Hospital | Peking University First Hospital | Reproductive & Genetic Hospital of CITIC-Xiangya | Qilu Hospital of Shandong University | Wuhan Union Hospital | Second Hospital of Jilin University | Shengjing Hospital | The First
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Gonal-f (Follitropin Alfa) is a Hormone drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Anovulation.
Product Name : Gonal-f
Product Type : Hormone
Upfront Cash : Inapplicable
January 12, 2015
Lead Product(s) : Follitropin Alfa
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Phase III
Sponsor : Peking University People's Hospital | Peking University First Hospital | Reproductive & Genetic Hospital of CITIC-Xiangya | Qilu Hospital of Shandong University | Wuhan Union Hospital | Second Hospital of Jilin University | Shengjing Hospital | The First
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Levonorgestrel
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Study Evaluating Levonorgestrel and Ethinyl Estradiol for Oral Contraception
Details : Levonorgestrel is a Hormone drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Contraceptives, Oral.
Product Name : Undisclosed
Product Type : Hormone
Upfront Cash : Inapplicable
December 27, 2013
Lead Product(s) : Levonorgestrel
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable